Joy Maulik, MSN, FNP-C, explains why a prostate cancer diagnosis should be seen as a change in direction, not an ending, and how patients can lean on education, their providers and caregivers.
|Articles|June 7, 2012
Continuous Hormone Therapy Better for Men With Advanced Prostate Cancer
Author(s)Jon Garinn
Men with metastatic prostate cancer lived longer with continuous hormone therapy compared with intermittent therapy.
Advertisement
In an international phase 3 trial, men with metastatic prostate cancer lived longer with continuous hormone therapy compared with intermittent therapy (5.8 years compared with 5.1 years). However, men with minimal metastases had an even greater benefit—nearly a two-year survival advantage.
The trial included more than 1,500 men with hormone-sensitive metastatic prostate cancer who were randomly assigned to receive intermittent or continuous hormone therapy. Prostate cancer can be fueled by androgens, such as testosterone, so hormone therapy is used to disrupt androgen production and stop the cancer’s growth. But because of the side effects of hormone therapy, which include reduced sexual drive and potency, hot flashes and weight gain, some doctors recommend intermittent treatment.
This new study shows that, despite the side effects, continuous treatment is more effective in men with less disease spread and comparably effective for those with more metastases.
Advertisement
Related to this article
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.
The FDA approved Talzenna plus Xtandi for adults with HRR-mutated metastatic prostate cancer that has not been treated with, or is still responding to, androgen pathway drugs.
Medicare will move ostomy supplies to eight national contracts in 2028. Survivors and clinicians say a poor fit can lead to leaks, infection and hospital stays.
An experimental treatment has kept one patient with heavily pretreated hairy cell leukemia free of detectable disease for more than two years, raising questions about whether CAR T-cell therapy could offer a path toward a cure.
The National Comprehensive Cancer Network released its first patient guideline written for caregivers on Oct. 27, 2026. The free guide covers emotional support, money, legal questions, medical tasks and caregivers' own well-being.
Three phase 3 trials presented at the 2026 ESMO Congress looked closely at swallowing, daily functioning and blood counts in throat, kidney and colorectal cancer. Here is what they found about living well during and after treatment.
New research found that nearly 1 in 5 second-level appeals for denied cancer medications under Medicare Part D were successful, raising questions about how insurers make coverage decisions and what patients can do when their treatment is denied.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
3 Quality-of-Life Results From ESMO 2026 Patients Should Know
3
4 Long-Term Survival Results From ESMO 2026 Patients Should Know
4
What New KRAS Drug Data From ESMO 2026 Mean for Patients
5